DERMBIONT
DermBiont is a biotech company that develops skin microbiome therapeutics to treat and prevent skin diseases. It is at the intersection of two highly active sectors: dermatology and the microbiome. They harness naturally occurring microbes on the human skin that have evolved over hundreds of thousands of years to compete with pathogenic microbes (fungi, bacteria, viruses, etc.). The company was founded in 2017 and is headquartered in Boston, Massachusetts with a satellite office in Emeryville, California.
DERMBIONT
Social Links:
Industry:
Biotechnology Health Care Medical Therapeutics
Founded:
2017-01-01
Address:
Boston, Massachusetts, United States
Country:
United States
Website Url:
http://www.dermbiont.com
Total Employee:
11+
Status:
Active
Total Funding:
66.07 M USD
Technology used in webpage:
Viewport Meta SPF SSL By Default LetsEncrypt Content Delivery Network Domain Not Resolving Amazon Organization Schema Google Apps For Business Microsoft Azure DNS
Current Advisors List
Current Employees Featured
Founder
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2021-12-21 | Chromaderm | Chromaderm acquired by DermBiont | N/A |
| 2020-10-21 | SeylanMED | SeylanMED acquired by DermBiont | N/A |
Investors List
Civilization Ventures
Civilization Ventures investment in Series A - DermBiont
Olive Tree Capital
Olive Tree Capital investment in Series A - DermBiont
Viking Global Investors
Viking Global Investors investment in Series A - DermBiont
Toba Capital
Toba Capital investment in Series A - DermBiont
Nan Fung Life Sciences
Nan Fung Life Sciences investment in Series A - DermBiont
Social Starts
Social Starts investment in Debt Financing - DermBiont
Joyance Partners
Joyance Partners investment in Debt Financing - DermBiont
Valia Ventures
Valia Ventures investment in Series A - DermBiont
Zola Global Investors
Zola Global Investors investment in Series A - DermBiont
Start Capital
Start Capital investment in Series A - DermBiont
Official Site Inspections
http://www.dermbiont.com
- Host name: 198.49.23.145
- IP address: 198.49.23.145
- Location: New York United States
- Latitude: 40.7157
- Longitude: -74
- Metro Code: 501
- Timezone: America/New_York
- Postal: 10013
More informations about "DermBiont"
DermBiont - Crunchbase Company Profile & Funding
DermBiont is a biotech company that develops skin microbiome therapeutics to treat and prevent skin diseases. It is at the intersection of two highly active sectors: dermatology and the microbiome. They harness naturally occurring …See details»
Leadership - DermBiont
Daniel Yadegar, M.D. Managing Partner at Double Point Ventures. Karl Beutner, M.D., Ph.D. Co-founder & CEO at DermBiont; previously CMO at Anacor (acquired by Pfizer for $5.2 billion) …See details»
DermBiont - Overview, News & Similar companies | ZoomInfo.com
Oct 25, 2023 Explore Complete Organization Structure. Is DermBiont your ideal customer? Let us give you the heads up on whether it's a good time to reach out. Last 7 days. ... - …See details»
DermBiont, Inc. - LinkedIn
DermBiont, Inc. is excited to announce positive initial data from our ongoing Phase 2a study with SM-020 for the treatment of #basalcellcarcinoma with 100% of treated tumors to date demonstrating ...See details»
DermBiont Company Profile 2024: Valuation, Funding …
When was DermBiont founded? DermBiont was founded in 2017. Where is DermBiont headquartered? DermBiont is headquartered in Emeryville, CA. What is the size of DermBiont? DermBiont has 22 total employees. What industry is …See details»
Overview - DermBiont
DermBiont is advancing targeted topical therapeutics for dermatological indications. Our products in development are all first-in-class with well-defined mechanisms of action and address the root cause of skin diseases. Sign up …See details»
DermBiont - Contacts, Employees, Board Members, Advisors
Organization. DermBiont . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 8. Number of Board …See details»
DermBiont - Funding, Financials, Valuation & Investors - Crunchbase
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Access exclusive financial …See details»
DermBiont Company Profile - Office Locations, Competitors ... - Craft
DermBiont develops skin microbiome therapeutics platform to treat and prevent skin diseases. It is leveraging skin microbiome therapeutics to advance its lead live bacterial product, DBI-001, …See details»
Skin Microbiome Startup DermBiont Raises $8M Series A to Treat …
Jun 18, 2019 DermBiont was co-founded in 2017 by Karl Beutner, M.D., Ph.D., Robert Brucker, Ph.D, and Nichola Eliovits. The company was incubated and funded by Olive Tree Capital until …See details»
DermBiont Announces 2024 Development Pipeline Update for its …
BOSTON, February 22, 2024--DermBiont, a clinical-stage biotechnology company that is advancing targeted topical therapeutics to address patient needs in three of the most …See details»
DermBiont Announces First Close of $35.2 Million in a Series B ...
Oct 24, 2023 DermBiont’s mission is to become the world’s leading precision dermatology company developing and commercializing targeted topical therapeutics that treat, cure, and …See details»
DermBiont Raises $28 Million and Acquires Chromaderm to …
Dec 21, 2021 DermBiont, Inc., a clinical-stage biotechnology company developing targeted topical therapeutics that address the root causes of skin diseases, announced today that it has …See details»
DermBiont Raises $28 Million and Acquires Chromaderm to …
Dec 21, 2021 About DermBiont DermBiont’s mission is to become the world’s leading precision dermatology company developing targeted topical therapeutics that treat, cure, and prevent …See details»
DermBiont raises $35.2m in Series B for dermatological therapies
Oct 25, 2023 DermBiont will also use SM-020 0.1% gel for 28-56 days in an open-label clinical extension in 25 additional subjects with SKs. For SM-030 gel, DermBiont will test the drug at …See details»
DermBiont raises $35.2M Series B to advance two topical skin …
Oct 25, 2023 Karl Beutner, DermBiont CEO. October 25, 2023 06:51 AM EDT. Financing. DermBiont raises $35.2M Series B to advance two dermatological drugs through PhII. …See details»
Pipeline - DermBiont
We are focused on developing targeted therapies that treat diseases of the skin at their root cause and fulfill the unmet needs of patients living with skin conditions.See details»
DermBiont Releases Positive Phase 2 Data for DBI-001 in Tinea …
Jan 8, 2021 Data from two, separate phase 2 clinical trials of investigational DBI-001 for the treatment of tinea pedis and atopic dermatitis show benefit, according to drug developer …See details»
Dermatology Platform — DermBiont
The problem: existing dermatology therapeutics primarily treat the symptoms of diseases with modest efficacy. DermBiont’s solution: leverage cutting edge innovation in dermatology and …See details»